Search - tctmd.com

Displaying 1 - 20 of 35

Sort: Relevancy | Date

News Conference News VIVA 2025

ENGULF Novel PE Thrombectomy Device Minimizes Blood Loss

L.A. McKeown

November 07, 2025

News Features

Imperfect Evidence: How Strong Is the Case for Transcatheter Tricuspid Valve Interventions?

Todd Neale

October 22, 2025

$Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis$

News Daily News

Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis

Todd Neale

August 13, 2025

News Daily News

Top Coronary Artery Disease News in 2024

Michael O'Riordan

December 26, 2024

ECLIPSE: Balloon Angioplasty as Good as Orbital Atherectomy in Calcified Lesions

News Conference News TCT 2024

ECLIPSE: Orbital Atherectomy No Better Than Balloon Angioplasty in Calcified Lesions

Yael L. Maxwell

October 29, 2024

News Daily News

Debating a PCI-First Strategy in Stable CAD: ORBITA-2 vs the Unconvinced

Michael O'Riordan

September 20, 2024

News Daily News

ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI

Michael O'Riordan

July 01, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2024

Shelley Wood

May 31, 2024

News Conference News EuroPCR 2024

ORBITA-2: Angina Phenotype Strongly Predicts PCI Response

Caitlin E. Cox

May 15, 2024

News Opinion CV Team Dispatch

May 2024 Dispatch for the CV Team

L.A. McKeown

May 01, 2024

News Conference News ACC 2024

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

L.A. McKeown

April 08, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

$Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)$

Presentation ACC 2024

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Presenter: Rasha K. Al-Lamee

April 08, 2024

News Daily News

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Michael O'Riordan

February 23, 2024

News Daily News

Two ‘Evidence-Based Pathways’ for Stable Angina: ORBITA-2 Editorial

Michael O'Riordan

December 27, 2023

News Daily News

Top Coronary Artery Disease News of 2023

Michael O'Riordan

December 22, 2023

News Conference News AHA 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Michael O'Riordan

November 11, 2023

News Daily News

Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry

Todd Neale

October 16, 2023

News Daily News

COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK

Michael O'Riordan

September 15, 2022

News Daily News

ORBITA Data Undercut the Idea PCI Does Best in Focal CAD

Caitlin E. Cox

August 06, 2021

Advertisement

ENGULF Novel PE Thrombectomy Device Minimizes Blood Loss

Imperfect Evidence: How Strong Is the Case for Transcatheter Tricuspid Valve Interventions?

Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis

Top Coronary Artery Disease News in 2024

ECLIPSE: Orbital Atherectomy No Better Than Balloon Angioplasty in Calcified Lesions

Debating a PCI-First Strategy in Stable CAD: ORBITA-2 vs the Unconvinced

ORBITA-STAR Highlights Variability in Symptom Changes Post-PCI

TCTMD’s Top 10 Most Popular Stories for May 2024

ORBITA-2: Angina Phenotype Strongly Predicts PCI Response

May 2024 Dispatch for the CV Team

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective

Two ‘Evidence-Based Pathways’ for Stable Angina: ORBITA-2 Editorial

Top Coronary Artery Disease News of 2023

Placebo-Controlled ORBITA-2 Shows PCI Eases Symptoms in Stable Angina

Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry

COURAGE and ORBITA Had No Impact on Elective PCI Rates in UK

ORBITA Data Undercut the Idea PCI Does Best in Focal CAD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content